Manipal Edu. And Medical Group (India) Signs MoU with German Company For Hospital Waste Management

Manipal Education and Medical Group (MEMG) has signed a memorandum of understanding (MoU) with Deuttsche Gesellschaft fur Technische Zusammenarbeit (GTZ), Germany, to set up a first of its kind state-of-the-art 'centre of excellence in waste management' at Manipal Hospital, Bangalore. The centre will develop intellectual properties in the field of environment management, while Manipal Academy of Higher Education (MAHE) will offer Diploma courses in the area of environmental and waste management.

Dr. Ranjan Pai, CEO, Manipal Education and Medical Group, said, "The Centre of Excellence for Waste Management will set new benchmark for healthcare industry in India." Dr. Jurgen Bischoff, Director, GTZ-ASEM, said, "A co-operation of this kind with private sector institution like Manipal and public sector institution like GTZ is vital to tackle environment issues. This co-operation is in line with the adoption of the charter of World Summit on Sustainability held in Johannesburg in 2002."

The benefits of the new system include water saving and consumption minimization. The system will work for both solid and liquid wastes. It will also upgrade the existing systems at Manipal Hospital for certification as per ISO 14000 protocols.

The five-decade old Manipal Education and Medical Group (MEMG) is the largest Hospital Management Group in Asia. It comprises 14 Teaching Hospitals (including specialized colleges of Dentistry, Allied Health, Nursing and Pharmacy), 6 Healthcare Systems with Bangalore, Manipal, Mangalore, Sikkim (Gangkot), Nepal (Pokhara) and Malaysia (Melaka) as hubs. The group also has 3 Feeder Hospitals, 19 Primary Healthcare Centres, and is currently running over 55 community Development projects. The super-specialist hospitals include Cancer Hospitals, Cardiac Hospitals, For Injection Disease Hospitals and Complimentary Clinics at several corporate houses.

(Ref : Chronicle Pharmabiz February 24, 2005)

Nymox's Alzheimer urine test kit to hit European markets

Nymox Pharmaceutical Corporation has entered into distribution agreements for the marketing and sale of its AlzheimAlert test kit with medical diagnostic companies in Europe.

The AlzheimAlert device technology uses patient urine samples to measure levels of biomarker for Alzheimer's disease, providing physicians with a valuable tool for the diagnostic of Alzheimer's disease. Nymox has announced the certification of its AlzheimAlert test kit with a CE Mark, making the device available for sale in the European Union.

The CE Marking indicates that a product complies with EU safety, environmental, and quality standards. Nymox has satisfactorily completed the testing and registration required to obtain CE Marking for the AlzheimAlert test kit device.

(Ref : Chronicle Pharmabiz February 24, 2005)